secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2022-09-12T23:59:59+00:00
Accession:  0001104659-22-099101
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead settles patent litigation for Descovy, Vemlidy, Odefsey; generic licenses begin 2031-2032
--------------------------------------------------------------------------------

- Agreements with Lupin, Apotex, Macleods, Hetero, Cipla resolve patent challenges for HIV drugs.
- License for Descovy and Vemlidy begins Oct 31, 2031; for Odefsey begins Jan 31, 2032, with earlier entry possible.
- Agreements filed with FTC and DOJ; dismissals filed in Delaware district court.
- Settlement removes litigation uncertainty but establishes generic entry timeline for key HIV portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000110465922099101/0001104659-22-099101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000110465922099101/tm2225634d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-099101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer